Literature DB >> 6224876

Platelet activation during steady state sickle cell disease.

J Westwick, E J Watson-Williams, S Krishnamurthi, G Marks, V Ellis, M F Scully, J M White, V V Kakkar.   

Abstract

Previous reports have given conflicting conclusions of the role platelets may play in initiating vaso-occlusive sickle cell crisis. Seven patients homozygous for sickle cell hemoglobin, and seven age, race and sex matched controls were each studied on at least two occasions in a six week period of normal health. The number of platelets circulating as aggregates, the plasma concentration of beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) were significantly elevated compared with controls. These findings were confirmed with a second series of fourteen patients and nine controls. Patient's platelets in plasma adjusted for both platelet number and citrate concentration aggregated more in response to low concentrations (0.4 and 1 microM) but less to higher concentrations (4 and 20 microM) of ADP and needed significantly more prostacyclin (PGI2) to inhibit ADP induced aggregation than did platelets from control subjects. There was no significant difference in plasma concentration of fibrinopeptide A and thromboxane (Tx)B2, nor in the platelet generation of TxB2 and release of serotonin and beta TG induced by aggregating agents. Thus, the platelets of patients with sickle cell anemia in the steady state are readily activated and respond in vivo by increased formation of aggregates and release of beta TG and PF-4.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224876

Source DB:  PubMed          Journal:  J Med        ISSN: 0025-7850


  19 in total

1.  P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease.

Authors:  Renata Polanowska-Grabowska; Kori Wallace; Joshua J Field; Lanlin Chen; Melissa A Marshall; Robert Figler; Adrian R L Gear; Joel Linden
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

2.  Structure-function relations of human hemoglobins.

Authors:  Alain J Marengo-Rowe
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-07

Review 3.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

Review 4.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 5.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

Review 6.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 7.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

8.  Platelets at the crossroads of thrombosis, inflammation and haemolysis.

Authors:  Sebastian Vogel; Swee Lay Thein
Journal:  Br J Haematol       Date:  2018-01-30       Impact factor: 6.998

9.  Morphological and functional platelet abnormalities in Berkeley sickle cell mice.

Authors:  Arun S Shet; Thomas J Hoffmann; Marketa Jirouskova; Christin A Janczak; Jacqueline R M Stevens; Adewole Adamson; Narla Mohandas; Elizabeth A Manci; Therese Cynober; Barry S Coller
Journal:  Blood Cells Mol Dis       Date:  2008-04-18       Impact factor: 3.039

Review 10.  Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Authors:  Gregory J Kato; Mark T Gladwin
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.